Impact of seven years of mass drug administration and recrudescence of Schistosoma haematobium infections after one year of treatment gap in Zanzibar: Repeated cross-sectional studies
- PMID: 33577601
- PMCID: PMC7880478
- DOI: 10.1371/journal.pntd.0009127
Impact of seven years of mass drug administration and recrudescence of Schistosoma haematobium infections after one year of treatment gap in Zanzibar: Repeated cross-sectional studies
Abstract
Background: Considerable progress towards the elimination of urogenital schistosomiasis was made by the Zanzibar Elimination of Schistosomiasis Transmission project from 2012 till 2016, when biannual praziquantel mass drug administration (MDA) alone or with additional snail control or behaviour change interventions were implemented. Annual MDA was continued in 2017 and 2018, but not in 2019, imposing a 16-month treatment gap. We monitored the Schistosoma haematobium prevalence from 2012 till 2020 and assessed recrudescence patterns with focus on 2020.
Methodology: Repeated cross-sectional surveys were conducted from 2011/12 till 2020 in 90 communities and 90 schools in Zanzibar. Annually, around 4,500 adults and up to 20,000 schoolchildren were surveyed. The S. haematobium prevalence was detected by urine filtration and reagent strips. In 2020, risk factors for infection were investigated using generalized estimated equation models.
Principal findings: In adults, the apparent S. haematobium prevalence was 3.9% in 2011 and 0.4% in 2020. In schoolchildren, the prevalence decreased from 6.6% in 2012 to 1.2% in 2019 with vicissitudes over the years. Prominent recrudescence of infection from 2.8% in 2019 to 9.1% (+225%) in 2020 was observed in 29 schools with historically moderate prevalences (≥10%). Compared with 2019, reinfection in 2020 was particularly striking in boys aged 9-16 years. Being male was a risk factor for infection in 2020 (adults: odds ratio (OR): 6.24, 95% confidence interval (95% CI): 1.96-19.60; schoolchildren: OR: 2.06, 95% CI: 1.52-2.78). Living near to a natural freshwater body significantly increased the odds of infection in adults (OR: 2.90, CI: 1.12-7.54).
Conclusions/significance: After 11 rounds of MDA over 7 years and a 16-month treatment gap, the urogenital schistosomiasis prevalence considerably rebounded in hotspot areas. Future elimination efforts in Zanzibar should focus on re-intensifying MDA plus additional interventions in hotspot areas. In low-prevalence areas, the strategy might be adapted from MDA to targeted surveillance-response.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
References
-
- GBD 2017 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1859–922. Epub 2018/11/13. 10.1016/S0140-6736(18)32335-3 - DOI - PMC - PubMed
-
- WHO. Schistosomiasis key facts 2020 [cited 2020 12.04.2020]. Available from: https://www.who.int/news-room/fact-sheets/detail/schistosomiasis.
-
- WHO. Ending the neglect to attain the Sustainable Development Goals—A road map for neglected tropical diseases 2021–2030. World Health Organization, 2020.
-
- Toor J, Rollinson D, Turner HC, Gouvras A, King CH, Medley GF, et al. Achieving elimination as a public health problem for Schistosoma mansoni and S. haematobium: When is community-wide treatment required? J Infect Dis. 2020;221(Supplement_5):S525–s30. Epub 2019/12/13. 10.1093/infdis/jiz609 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
